Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Complicanze vascolari dopo il trapianto renale (DAN-PTRAIII)

12 ottobre 2026 aggiornato da: University of Aarhus

Complicanze Vascolari Dopo il Trapianto di Rene: Uno Studio Prospettico Nazionale Multicentrico - Lo Studio DAN-PTRAIII

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

Tipo di studio

Osservativo

Iscrizione (Stimato)

60

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Mark Reinhard, MD, PhD
  • Numero di telefono: +45 40460321
  • Email: markrein@rm.dk

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

Descrizione

Inclusion Criteria:

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.

  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.

  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Concurrent biopsy demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Kidney Transplant Recipients

Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

Catheter-based angiography performed in accordance with the study protocol.

Measurement of translesional pressure gradients performed in accordance with the study protocol.

Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in measured glomerular filtration rate (mGFR).
Lasso di tempo: Baseline and 3 months post-PTA.

Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

Baseline and 3 months post-PTA.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in estimated glomerular filtration rate (eGFR).
Lasso di tempo: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
Lasso di tempo: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Lasso di tempo: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
Lasso di tempo: Baseline and 3 months post-PTA.

Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline.

Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Baseline and 3 months post-PTA.
Number of clinical events after PTA.
Lasso di tempo: 10 years post-PTA.

Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:

  1. Cardiovascular death
  2. Renal death
  3. Death from non-cardiovascular and non-renal causes
  4. Undetermined cause of death
  5. Stroke
  6. Myocardial infarction
  7. Hospitalization for heart failure
  8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease
  9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days
  10. Biopsy-proven rejection
  11. Need for repeat PTA due to restenosis or in-stent thrombosis
  12. Other relevant clinical events
10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
Lasso di tempo: 30 days post-PTA.

All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):

  1. Vessel rupture
  2. Vessel dissection
  3. Vessel occlusion
  4. Vessel perforation
  5. Stent thrombosis
  6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route)
  7. Pulmonary oedema
  8. Major bleeding requiring transfusion
  9. Embolisation due to bleeding or another adverse event
  10. Nephrectomy due to bleeding or another adverse event
  11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention
  12. Requirement for acute dialysis
  13. Clinical events, including all-cause mortality, as defined above
  14. Other relevant adverse events (AEs)
30 days post-PTA.
Doppler ultrasound.
Lasso di tempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
Lasso di tempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Intravascular ultrasound.
Lasso di tempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Lasso di tempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
Lasso di tempo: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Mark Reinhard, MD, PhD, Aarhus University Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

22 maggio 2026

Completamento primario (Stimato)

31 marzo 2031

Completamento dello studio (Stimato)

1 giugno 2031

Date di iscrizione allo studio

Primo inviato

1 aprile 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 aprile 2026

Primo Inserito (Effettivo)

15 aprile 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 ottobre 2026

Ultimo verificato

1 maggio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .